Ling Tao1, Quan Wang2, Ding Liu3, Jing Wang4, Ziqing Zhu1, Li Feng5. 1. XiangYa School of Medicine, Central South University, Changsha, Hunan, China. 2. Key Laboratory of Biomedical Spectroscopy of Xi' An, Key Laboratory of Spectral Imaging technology, Xi'an, Institute of Optics and Precision Mechanics (XIOPM), Chinese Academy of Sciences, Xi' An, China. 3. Department of Neurology, The Third Xiangya Hospital, Central South University, Changsha, Hunan, China. 4. Department of Neurology, Xiangya Hospital, Central South University, Changsha, Hunan, China. 5. Department of Neurology, Xiangya Hospital, Central South University, Changsha, Hunan, China. fenglihx@163.com.
Abstract
PURPOSE OF REVIEW: Eye tracking is a powerful method to investigate the relationship between behavior and neural mechanisms. In recent years, eye movement analysis has been used in patients with neurological disorders to assess cognitive function. In this review, we explore the latest eye tracking researches in neurological disorders that are commonly associated with cognitive deficits, specifically, amyotrophic lateral sclerosis (ALS), Alzheimer's disease (AD), Parkinson's disease (PD), multiple sclerosis (MS), and epilepsy. We focus on the application of ocular measures in these disorders, with the goal of understanding how eye tracking technology can be used in the clinical setting. FINDINGS: Eye tracking tasks (especially saccadic tasks) are often used as an adjunct to traditional scales for cognitive assessment. Eye tracking data confirmed that executive dysfunction is common in PD and ALS, whereas AD and MS are characterized by attention deficits. Research in evaluating cognitive function in epilepsy using eye tracking is still in its early stages, but this approach has shown advantages as a sensitive quantitative method with high temporal and spatial resolution. Eye tracking technology can facilitate the assessment of cognitive impairment with higher temporal resolution and finer granularity than traditional cognitive assessment. Oculomotor data collected during cognitive tasks can provide insight into biological processes. Eye tracking provides a nonverbal and less cognitively demanding method of measuring disease progression in cognitively impaired patients.
PURPOSE OF REVIEW: Eye tracking is a powerful method to investigate the relationship between behavior and neural mechanisms. In recent years, eye movement analysis has been used in patients with neurological disorders to assess cognitive function. In this review, we explore the latest eye tracking researches in neurological disorders that are commonly associated with cognitive deficits, specifically, amyotrophic lateral sclerosis (ALS), Alzheimer's disease (AD), Parkinson's disease (PD), multiple sclerosis (MS), and epilepsy. We focus on the application of ocular measures in these disorders, with the goal of understanding how eye tracking technology can be used in the clinical setting. FINDINGS: Eye tracking tasks (especially saccadic tasks) are often used as an adjunct to traditional scales for cognitive assessment. Eye tracking data confirmed that executive dysfunction is common in PD and ALS, whereas AD and MS are characterized by attention deficits. Research in evaluating cognitive function in epilepsy using eye tracking is still in its early stages, but this approach has shown advantages as a sensitive quantitative method with high temporal and spatial resolution. Eye tracking technology can facilitate the assessment of cognitive impairment with higher temporal resolution and finer granularity than traditional cognitive assessment. Oculomotor data collected during cognitive tasks can provide insight into biological processes. Eye tracking provides a nonverbal and less cognitively demanding method of measuring disease progression in cognitively impairedpatients.
Authors: Nicole H Yuen; Fred Tam; Nathan W Churchill; Tom A Schweizer; Simon J Graham Journal: Front Hum Neurosci Date: 2021-08-16 Impact factor: 3.169
Authors: Francesca D'Addio; Ida Pastore; Cristian Loretelli; Alessandro Valderrama-Vasquez; Vera Usuelli; Emma Assi; Chiara Mameli; Maddalena Macedoni; Anna Maestroni; Antonio Rossi; Maria Elena Lunati; Paola Silvia Morpurgo; Alessandra Gandolfi; Laura Montefusco; Andrea Mario Bolla; Moufida Ben Nasr; Stefania Di Maggio; Lisa Melzi; Giovanni Staurenghi; Antonio Secchi; Stefania Bianchi Marzoli; Gianvincenzo Zuccotti; Paolo Fiorina Journal: Acta Diabetol Date: 2022-06-22 Impact factor: 4.087
Authors: Sanna Hannonen; Sami Andberg; Virve Kärkkäinen; Minna Rusanen; Juha-Matti Lehtola; Toni Saari; Ville Korhonen; Laura Hokkanen; Merja Hallikainen; Tuomo Hänninen; Ville Leinonen; Kai Kaarniranta; Roman Bednarik; Anne M Koivisto Journal: J Alzheimers Dis Date: 2022 Impact factor: 4.160